Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
Authors
Keywords
-
Journal
PHARMACOTHERAPY
Volume 40, Issue 5, Pages 416-437
Publisher
Wiley
Online
2020-04-08
DOI
10.1002/phar.2398
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
- (2020) Qiurong Ruan et al. INTENSIVE CARE MEDICINE
- Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore
- (2020) Barnaby Edward Young et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
- (2020) Dawei Wang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
- (2020) Calvin J Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
- (2020) Clark D Russell et al. LANCET
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
- (2020) Roujian Lu et al. LANCET
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
- (2020) Nanshan Chen et al. LANCET
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Convalescent plasma as a potential therapy for COVID-19
- (2020) Long Chen et al. LANCET INFECTIOUS DISEASES
- COVID-19: combining antiviral and anti-inflammatory treatments
- (2020) Justin Stebbing et al. LANCET INFECTIOUS DISEASES
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
- (2020) Guangdi Li et al. NATURE REVIEWS DRUG DISCOVERY
- Defining the Epidemiology of Covid-19 — Studies Needed
- (2020) Marc Lipsitch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases
- (2020) Tao Ai et al. RADIOLOGY
- The COVID‐19 epidemic
- (2020) Thirumalaisamy P. Velavan et al. TROPICAL MEDICINE & INTERNATIONAL HEALTH
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
- (2020) Timothy P. Sheahan et al. Nature Communications
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
- (2020) Xiaobo Yang et al. Lancet Respiratory Medicine
- Pathological findings of COVID-19 associated with acute respiratory distress syndrome
- (2020) Zhe Xu et al. Lancet Respiratory Medicine
- Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks
- (2020) Hossam M. Ashour et al. Pathogens
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- (2020) Xueting Yao et al. CLINICAL INFECTIOUS DISEASES
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- COVID-19: consider cytokine storm syndromes and immunosuppression
- (2020) Puja Mehta et al. LANCET
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
- (2020) Jianjun Gao et al. BioScience Trends
- Implications of COVID-19 for patients with pre-existing digestive diseases
- (2020) Ren Mao et al. Lancet Gastroenterology & Hepatology
- Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness
- (2019) Ana E Gamiño-Arroyo et al. CLINICAL INFECTIOUS DISEASES
- Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge
- (2019) Michael K. Lo et al. Science Translational Medicine
- Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
- (2019) Egor Tchesnokov et al. Viruses-Basel
- Ribavirin and Interferon Therapy for Critically Ill Patients with the Middle East Respiratory Syndrome: A multicenter observational study
- (2019) Yaseen Arabi et al. CLINICAL INFECTIOUS DISEASES
- Therapeutic strategies to target the Ebola virus life cycle
- (2019) Thomas Hoenen et al. NATURE REVIEWS MICROBIOLOGY
- A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
- (2019) Sabue Mulangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
- (2018) Yaseen M. Arabi et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
- (2018) Maria L. Agostini et al. mBio
- Middle East Respiratory Syndrome
- (2017) Yaseen M. Arabi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
- (2017) Timothy P. Sheahan et al. Science Translational Medicine
- Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials
- (2016) Vincent Madelain et al. CLINICAL PHARMACOKINETICS
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
- (2016) Travis K. Warren et al. NATURE
- A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs
- (2015) Jianzhong Cao et al. ANTIVIRAL RESEARCH
- Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
- (2015) Jasper Fuk-Woo Chan et al. JOURNAL OF INFECTIOUS DISEASES
- Nitazoxanide: A first-in-class broad-spectrum antiviral agent
- (2014) Jean-François Rossignol ANTIVIRAL RESEARCH
- Arbidol as a broad-spectrum antiviral: An update
- (2014) Julie Blaising et al. ANTIVIRAL RESEARCH
- Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone
- (2014) Anil Pareek et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial
- (2014) Jason Haffizulla et al. LANCET INFECTIOUS DISEASES
- Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study
- (2014) Ali S Omrani et al. LANCET INFECTIOUS DISEASES
- Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment
- (2013) S. K. P. Lau et al. JOURNAL OF GENERAL VIROLOGY
- Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
- (2013) Darryl Falzarano et al. Scientific Reports
- Administration of antiretroviral medication via enteral tubes
- (2012) E. S. Prohaska et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides
- (2012) Aesop Cho et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
- (2011) Mark S. Sulkowski et al. Nature Reviews Gastroenterology & Hepatology
- Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin
- (2009) E. Vets et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational Level
- (2009) Jean François Rossignol et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Study of the In Vitro Activities of Rifaximin and Comparator Agents against 536 Anaerobic Intestinal Bacteria from the Perspective of Potential Utility in Pathology Involving Bowel Flora
- (2008) S. M. Finegold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Human immunopathogenesis of severe acute respiratory syndrome (SARS)
- (2007) Mark J. Cameron et al. VIRUS RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More